Izervay Patent Expiration

Izervay is a drug owned by Astellas Pharma Us Inc. It is protected by 8 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 11, 2034. Details of Izervay's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US9617546 Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(4 months from now)

Active
US10947544 Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(4 months from now)

Active
US7803931 Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(4 months from now)

Active
US7538211 Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(4 months from now)

Active
US7579456 Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(4 months from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491176 Methods for treating or preventing ophthalmological conditions
Jul, 2034

(9 years from now)

Active
US11273171 Methods for treating or preventing ophthalmological conditions
Jul, 2034

(9 years from now)

Active
US8236773 Aptamer therapeutics useful in the treatment of complement-related disorders
Nov, 2026

(2 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Izervay's patents.

Given below is the list of recent legal activities going on the following patents of Izervay.

Activity Date Patent Number
Patent litigations
Initial letter Re: PTE Application to regulating agency 26 Mar, 2024 US8236773
Initial letter Re: PTE Application to regulating agency 26 Mar, 2024 US9617546
Initial letter Re: PTE Application to regulating agency 26 Mar, 2024 US7579456
Initial letter Re: PTE Application to regulating agency 26 Mar, 2024 US11273171
Payment of Maintenance Fee, 12th Year, Large Entity 07 Feb, 2024 US8236773
Patent Term Extension Application under 35 USC 156 Filed 27 Sep, 2023 US11273171
Patent Term Extension Application under 35 USC 156 Filed 27 Sep, 2023 US9617546
Patent Term Extension Application under 35 USC 156 Filed 27 Sep, 2023 US7579456
Patent Term Extension Application under 35 USC 156 Filed 27 Sep, 2023 US8236773
Post Issue Communication - Certificate of Correction 15 Sep, 2023 US11273171

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Izervay is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Izervay's family patents as well as insights into ongoing legal events on those patents.

Izervay's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Izervay's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 11, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Izervay Generics:

There are no approved generic versions for Izervay as of now.





About Izervay

Izervay is a drug owned by Astellas Pharma Us Inc. It is used for treating geographic atrophy secondary to age-related macular degeneration. Izervay uses Avacincaptad Pegol Sodium as an active ingredient. Izervay was launched by Astellas in 2023.

Approval Date:

Izervay was approved by FDA for market use on 04 August, 2023.

Active Ingredient:

Izervay uses Avacincaptad Pegol Sodium as the active ingredient. Check out other Drugs and Companies using Avacincaptad Pegol Sodium ingredient

Treatment:

Izervay is used for treating geographic atrophy secondary to age-related macular degeneration.

Dosage:

Izervay is available in solution form for intravitreal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) SOLUTION Prescription INTRAVITREAL